 Hepion begins the crucial year 2022, where it will finally be determined whether CRV431 possesses anti-fibroticanti-inflammatory activity in NASH patients. In the case of positive data Fibroscan, ELF score, etc., it would not be strange to see revaluations in the share prices of x3 or even x4. 